Quidel (NASDAQ:QDEL) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a report issued on Monday.

Other equities analysts also recently issued reports about the stock. TheStreet raised shares of Quidel from a “c+” rating to a “b” rating in a report on Wednesday, November 7th. Zacks Investment Research downgraded shares of Quidel from a “buy” rating to a “hold” rating in a report on Friday, November 9th. Piper Jaffray Companies reissued an “overweight” rating and set a $74.00 price target on shares of Quidel in a report on Wednesday, August 8th. BidaskClub raised shares of Quidel from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 15th. Finally, Canaccord Genuity lifted their price target on shares of Quidel from $75.00 to $78.00 and gave the company a “buy” rating in a report on Tuesday, August 14th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $74.14.

NASDAQ:QDEL opened at $62.99 on Monday. The stock has a market cap of $2.60 billion, a PE ratio of -899.86, a price-to-earnings-growth ratio of 1.03 and a beta of 1.05. Quidel has a 52 week low of $33.01 and a 52 week high of $77.63. The company has a quick ratio of 0.86, a current ratio of 1.26 and a debt-to-equity ratio of 0.21.

Quidel (NASDAQ:QDEL) last released its quarterly earnings data on Tuesday, November 6th. The company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.16. The company had revenue of $117.40 million during the quarter, compared to the consensus estimate of $120.09 million. Quidel had a net margin of 7.26% and a return on equity of 25.63%. The firm’s revenue for the quarter was up 130.6% compared to the same quarter last year. During the same period last year, the firm earned $0.17 EPS. On average, equities research analysts expect that Quidel will post 2.55 EPS for the current year.

In other Quidel news, CEO Douglas C. Bryant sold 7,217 shares of the business’s stock in a transaction dated Wednesday, October 31st. The shares were sold at an average price of $65.10, for a total value of $469,826.70. Following the completion of the transaction, the chief executive officer now directly owns 301,530 shares of the company’s stock, valued at $19,629,603. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Robert Joseph Bujarski sold 38,550 shares of the business’s stock in a transaction dated Friday, August 17th. The stock was sold at an average price of $70.15, for a total transaction of $2,704,282.50. Following the completion of the transaction, the senior vice president now directly owns 26,153 shares of the company’s stock, valued at $1,834,632.95. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 147,067 shares of company stock valued at $10,204,720. Insiders own 16.70% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in QDEL. Eagle Asset Management Inc. raised its stake in shares of Quidel by 225.8% in the third quarter. Eagle Asset Management Inc. now owns 652,048 shares of the company’s stock worth $42,493,000 after acquiring an additional 451,940 shares during the last quarter. Carillon Tower Advisers Inc. bought a new position in shares of Quidel in the third quarter worth about $25,294,000. BlackRock Inc. raised its stake in shares of Quidel by 22.2% in the second quarter. BlackRock Inc. now owns 2,188,930 shares of the company’s stock worth $145,564,000 after acquiring an additional 396,989 shares during the last quarter. Rothschild Asset Management Inc. bought a new position in shares of Quidel in the second quarter worth about $25,441,000. Finally, Fuller & Thaler Asset Management Inc. bought a new position in shares of Quidel in the second quarter worth about $12,857,000. 88.29% of the stock is owned by institutional investors.

About Quidel

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus products point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.

Featured Story: Fundamental Analysis and Choosing Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Quidel (NASDAQ:QDEL)

Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.